We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.
| Name | Symbol | Market | Type |
|---|---|---|---|
| GSK plc | NYSE:GSK | NYSE | Depository Receipt |
| Price Change | % Change | Price | High Price | Low Price | Open Price | Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|
| 0.23 | 0.53% | 43.58 | 43.68 | 43.27 | 43.58 | 4,048,068 | 01:00:00 |
From Nov 2023 to May 2024
By Christian Moess Laursen
GSK said it has received a positive opinion recommending the approval of its blood-cancer treatment momelotinib from the European Medicines Agency.
The British pharmaceutical giant said the decision on marketing authorization in the EU is expected by early 2024.
The positive opinion was adopted by the Committee for Medicinal Products for Human Use--or CHMP--of the European Medicines Agency, and is one of the final steps prior to marketing authorization decision by the European Commission.
If approved, momelotinib would be the only medicine in the EU specifically for both newly diagnosed and previously treated patients with myelofibrosis--a rare type of blood cancer--and moderate to severe anaemia, that addresses enlarged spleen and symptoms.
Write to Christian Moess Laursen at christian.moess@wsj.com
(END) Dow Jones Newswires
November 13, 2023 02:34 ET (07:34 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.
1 Year GSK Chart |
1 Month GSK Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
